PIK3C3 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:5289, HGNC:8974, MIM:602609, NM_001308020, NM_002647, NP_001294949, NP_002638, PIK3C3, VPS34, Vps34, XM_011526031, XP_011524333, XR_001753204, XR_002958176, XR_935226, hVps34, phosphatidylinositol 3-kinase catalytic subunit type 3

Omim:OMIM:602609

Id:ENSG00000078142

Hgnc:HGNC:8974

Entrez:5289

Ensembl:ENSG00000078142

Description:phosphatidylinositol 3-kinase catalytic subunit type 3

Enables 1-phosphatidylinositol-3-kinase activity. Involved in early endosome to late endosome transport and regulation of cytokinesis. Acts upstream of or within autophagy and protein lipidation. Located in autolysosome; late endosome; and midbody. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View PIK3C3's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with PIK3C3.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using PIK3C3.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for PIK3C3.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with PIK3C3.

Results found

Linked to

	Label	Description
	GSE216273,GSE216292 14 V 6 PALBOCICLIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 progesterone fibroblast 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 0 V 3 PALMITIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE229973 3 V 2 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE148200 0 V 2 GEMCITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 7 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 2 V 7 PIRFENIDONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE165334 2 V 0 DABRAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 12 V 6 PALMITIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

GSE216273,GSE216292 14 V 6 PALBOCICLIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE220806 progesterone fibroblast 1 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 6 v 11 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 0 V 3 PALMITIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE229973 3 V 2 CISPLATIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE148200 0 V 2 GEMCITABINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 7 v 5 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE226249 2 V 7 PIRFENIDONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE165334 2 V 0 DABRAFENIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 12 V 6 PALMITIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.